Hospital

Investigational targeted B-cell therapy demonstrates superior efficacy compared with teriflunomide, a commonly prescribed treatment for MS.

Ozanimod (Zeposia) is indicated for the treatment of multiple sclerosis and moderately to severely active ulcerative colitis in adults.

Atezolizumab meets its primary endpoint of overall survival for patients with resected non-small cell lung cancer across most subgroups.

Device provides tailored relief to multiple pain areas and adds more treatment options for evolving conditions.

Tranexamic acid indicated for patients with hemophilia for short-term use to reduce or prevent hemorrhage and decrease the need for replacement therapy during and following tooth extraction.

New research suggests that icosapent ethyl can significantly decrease cardiovascular risk among former or current smokers with other cardiovascular risk factors.

New research indicates that COVID-19 vaccinations did not increase the risks of preterm births or gestational issues for pregnant women, despite prior conflicting evidence.

Analysis shows that myocarditis was the most commonly diagnosed condition associated with pediatric post-acute sequelae of SARS-CoV-2.

Meropenem IV is an antibacterial medication indicated for the treatment of complicated stomach and skin structure infections.

Following the seemingly endless disruptions to the country’s supply chain over the past 2-year period, signs are showing more pain before things get better.

Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.

Risk factors associated with declining health-related quality of life for adult survivors of childhood cancer, such as physical inactivity and chronic health conditions, should be targets of surveillance and intervention.

Canakinumab did not meet the primary endpoint of disease-free survival in adult patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer.

In a recent survey, researchers identified rising costs, socioeconomic inequity, and drug trends as major concerns for large employers.

Analysis is based on previously reported data collected in March and April 2022, with the FDA granting emergency use authorization for individuals aged 6 months to 4 years on June 17.

Pharmacists, being one of the most accessible health care professionals, are critical pieces of the opioid tapering program puzzle.

As pharmacists take on new responsibilities, researchers have been studying the effects of pharmacists on interprofessional care teams.

The vaccine candidate is composed of 2 preF proteins selected to optimize protection against the RSV A and B strains.

During the surge caused by the Delta variant, a third dose of the Pfizer-BioNTech COVID-19 vaccine reduced infections and COVID-19-related hospitalizations and deaths among patients in long term care facilities.

Overall rates of early-stage cervical cancer in the United States have been falling, but cases with advanced disease are continuing to rise.

Ibrutinib (Imbruvica) is the first therapy to gain FDA approval for younger patients who had no prior treatment options for chronic graft-versus-host disease.

Zynteglo is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions.

Early detection of chronic kidney disease is vital to preventing comorbid conditions.

The phase 2 study will evaluate the efficacy and safety of 2 different doses of MK-2060 in patients with ESRD receiving hemodialysis via an arteriovenous graft.

The 4 academic centers will evaluate the role of telehealth in areas such as prevention, screening, diagnosis, treatment, and survivorship.

Analysis includes nearly 43 million individuals aged 13 year and older who received at least 1 dose in England between December 1, 2020, and December 15, 2021.

Survey data indicates that people experiencing homelessness had a lower annual incidence of COVID-19 despite having a higher burden of infectious diseases, suggesting opportunities for better integration of homelessness status in infectious disease reporting.